PIPE-307 + Placebo oral tablet

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Feb 26, 2021 โ†’ Sep 1, 2021

About PIPE-307 + Placebo oral tablet

PIPE-307 + Placebo oral tablet is a phase 1 stage product being developed by Contineum Therapeutics for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04725175. Target conditions include Multiple Sclerosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04725175Phase 1Completed